FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285476> ?p ?o ?g. }

• W4379285476 endingPage "e13594" @default.
• W4379285476 startingPage "e13594" @default.
• W4379285476 abstract "e13594 Background: Facilitating personalized medicine and applying precision oncology in treating breast cancer (BC) requires in vitro model systems that mimic the disease's heterogeneity and the clinical response to cancer treatment. The capability of patient-derived organoids (PDOs) to serve as a paramount model in this regard has been shown. Nonetheless, offering this model in a clinically relevant timeframe to support clinical decisions persists challenging. Methods: To examine the feasibility of PDOs as a precision oncology platform to guide treatment decisions in the clinic, we are conducting a prospective exploratory study to establish PDOs from core needle biopsies and surgical samples and evaluate Onco-PDO drug testing in a short timeframe (10-14 days) after biopsy. In addition, PDOs are further expanded and characterized histologically, genomically, and biobanked. More importantly, the clinical response of patients is monitored and correlated with the PDO drug response. Results: To date, 85 tumor samples from the primary tumor (n=64) and lymph node metastases (n=21) were received from 73 patients recruited in our ongoing prospective exploratory study in the Invitrocue Munich laboratory. The median age stands at 51 years (range 28-85). The success rate of PDO generation holds at 90%. Up to now, the Onco-PDO test has been successfully performed in 75% of cases (n=64) and failed in 25% (n=21). A broad spectrum of standard-of-care chemotherapeutic and targeted drugs in BC were tested, resulting in 942 readouts. The heatmap of drug screening indicates the highest sensitivity to anthracyclines such as epirubicin (E) and doxorubicin (D) as a single agent or in combination with cyclophosphamide (EC and DC). In other drugs a higher variability in the range of drug sensitivity has been observed: i.e., paclitaxel (T; 0-98%), carboplatin (C; 0-99%), and the combination (TC; 0-99%), as well as 5-FU (0-100%) and vinorelbine (0-95%). Thus far, the analysis of clinical correlation could be performed in patients who received epirubicin resulting in a significant difference (p=0.03) in the IC-50 of epirubicin between responder and non-responder patients. Conclusions: The prospective exploratory study using Onco-PDO test by Invitrocue could overcome the previous challenges concerning the implementation of PDOs in clinical practice by standardizing the methodology for PDO generation especially from small starting material such as core needle biopsies and drug testing more rapidly and efficiently, leading to providing results within a clinically relevant timeframe of 14 days after obtaining a biopsy. The onco-PDO test might serve as an ideal test enabling precision oncology by identifying effective treatments and sparing unnecessary side effects from ineffective treatments." @default.
• W4379285476 created "2023-06-05" @default.
• W4379285476 creator A5001164379 @default.
• W4379285476 creator A5018361553 @default.
• W4379285476 creator A5018744564 @default.
• W4379285476 creator A5032853201 @default.
• W4379285476 creator A5044887899 @default.
• W4379285476 creator A5054109395 @default.
• W4379285476 creator A5056873538 @default.
• W4379285476 creator A5061219173 @default.
• W4379285476 creator A5062487174 @default.
• W4379285476 creator A5063916889 @default.
• W4379285476 creator A5066200247 @default.
• W4379285476 creator A5077979638 @default.
• W4379285476 creator A5079436601 @default.
• W4379285476 creator A5080379706 @default.
• W4379285476 creator A5090651619 @default.
• W4379285476 creator A5092084525 @default.
• W4379285476 creator A5092084526 @default.
• W4379285476 date "2023-06-01" @default.
• W4379285476 modified "2023-10-14" @default.
• W4379285476 title "Onco-PDO test utilizing patient-derived organoids (PDOs) and next-generation precision oncology in breast cancer." @default.
• W4379285476 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13594" @default.
• W4379285476 hasPublicationYear "2023" @default.
• W4379285476 type Work @default.
• W4379285476 citedByCount "0" @default.
• W4379285476 crossrefType "journal-article" @default.
• W4379285476 hasAuthorship W4379285476A5001164379 @default.
• W4379285476 hasAuthorship W4379285476A5018361553 @default.
• W4379285476 hasAuthorship W4379285476A5018744564 @default.
• W4379285476 hasAuthorship W4379285476A5032853201 @default.
• W4379285476 hasAuthorship W4379285476A5044887899 @default.
• W4379285476 hasAuthorship W4379285476A5054109395 @default.
• W4379285476 hasAuthorship W4379285476A5056873538 @default.
• W4379285476 hasAuthorship W4379285476A5061219173 @default.
• W4379285476 hasAuthorship W4379285476A5062487174 @default.
• W4379285476 hasAuthorship W4379285476A5063916889 @default.
• W4379285476 hasAuthorship W4379285476A5066200247 @default.
• W4379285476 hasAuthorship W4379285476A5077979638 @default.
• W4379285476 hasAuthorship W4379285476A5079436601 @default.
• W4379285476 hasAuthorship W4379285476A5080379706 @default.
• W4379285476 hasAuthorship W4379285476A5090651619 @default.
• W4379285476 hasAuthorship W4379285476A5092084525 @default.
• W4379285476 hasAuthorship W4379285476A5092084526 @default.
• W4379285476 hasConcept C121608353 @default.
• W4379285476 hasConcept C126322002 @default.
• W4379285476 hasConcept C142724271 @default.
• W4379285476 hasConcept C143998085 @default.
• W4379285476 hasConcept C163763905 @default.
• W4379285476 hasConcept C188816634 @default.
• W4379285476 hasConcept C2780835546 @default.
• W4379285476 hasConcept C32220436 @default.
• W4379285476 hasConcept C530470458 @default.
• W4379285476 hasConcept C60644358 @default.
• W4379285476 hasConcept C71924100 @default.
• W4379285476 hasConcept C86803240 @default.
• W4379285476 hasConceptScore W4379285476C121608353 @default.
• W4379285476 hasConceptScore W4379285476C126322002 @default.
• W4379285476 hasConceptScore W4379285476C142724271 @default.
• W4379285476 hasConceptScore W4379285476C143998085 @default.
• W4379285476 hasConceptScore W4379285476C163763905 @default.
• W4379285476 hasConceptScore W4379285476C188816634 @default.
• W4379285476 hasConceptScore W4379285476C2780835546 @default.
• W4379285476 hasConceptScore W4379285476C32220436 @default.
• W4379285476 hasConceptScore W4379285476C530470458 @default.
• W4379285476 hasConceptScore W4379285476C60644358 @default.
• W4379285476 hasConceptScore W4379285476C71924100 @default.
• W4379285476 hasConceptScore W4379285476C86803240 @default.
• W4379285476 hasIssue "16_suppl" @default.
• W4379285476 hasLocation W43792854761 @default.
• W4379285476 hasOpenAccess W4379285476 @default.
• W4379285476 hasPrimaryLocation W43792854761 @default.
• W4379285476 hasRelatedWork W1979057726 @default.
• W4379285476 hasRelatedWork W2060697677 @default.
• W4379285476 hasRelatedWork W2224319365 @default.
• W4379285476 hasRelatedWork W2351758673 @default.
• W4379285476 hasRelatedWork W2376759146 @default.
• W4379285476 hasRelatedWork W2554808068 @default.
• W4379285476 hasRelatedWork W2603702255 @default.
• W4379285476 hasRelatedWork W377899687 @default.
• W4379285476 hasRelatedWork W4282049732 @default.
• W4379285476 hasRelatedWork W4291016733 @default.
• W4379285476 hasVolume "41" @default.
• W4379285476 isParatext "false" @default.
• W4379285476 isRetracted "false" @default.
• W4379285476 workType "article" @default.